Evorpacept (CD47) + Lenalidomide/Rituximab Achieves 80% CR in R/R B-NHL (Phase I)

Evorpacept (ALX148) is a high-affinity CD47 blocker with an inactive Fc to promote macrophage phagocytosis while limiting cytopenias; added to lenalidomide and rituximab (R2) in a single-arm Phase I (n=20; ≥2 prior lines; 90% indolent; NCT05025800), it produced 80% CR and 2-yr PFS 69%, with grade≥3 AEs of neutropenia 60%, infections 30%, and ALT increase 15% (no DLTs). Set against R2 alone—AUGMENT’s median PFS 39.4 mo with grade≥3 neutropenia 50% and MAGNIFY’s CR ~42%—the depth of remission looks higher while durability sits within the R2 range, acknowledging small, nonrandomized data.